345 related articles for article (PubMed ID: 32532840)
1. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
2. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
3. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
4. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
5. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
[TBL] [Abstract][Full Text] [Related]
6. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
[TBL] [Abstract][Full Text] [Related]
7. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.
Bessard A; Solé V; Bouchaud G; Quéméner A; Jacques Y
Mol Cancer Ther; 2009 Sep; 8(9):2736-45. PubMed ID: 19723883
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
[TBL] [Abstract][Full Text] [Related]
9. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
[TBL] [Abstract][Full Text] [Related]
10. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
11. Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation.
Perdreau H; Mortier E; Bouchaud G; Solé V; Boublik Y; Plet A; Jacques Y
Eur Cytokine Netw; 2010 Dec; 21(4):297-307. PubMed ID: 21078585
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
Zhao L; Wang WJ; Zhang JN; Zhang XY
Asian Pac J Cancer Prev; 2014; 15(9):4039-44. PubMed ID: 24935593
[TBL] [Abstract][Full Text] [Related]
13. Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells.
Miyazato K; Tahara H; Hayakawa Y
Cancer Sci; 2020 Aug; 111(8):2770-2778. PubMed ID: 32573072
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
Hafner M; Falk W; Echtenacher B; Männel DN
Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
Qi L; Zhang Q; Miao Y; Kang W; Tian Z; Xu D; Xiao W; Fang F
Int J Cancer; 2020 Mar; 146(5):1421-1434. PubMed ID: 31709531
[TBL] [Abstract][Full Text] [Related]
16. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β.
Brownlie D; Doughty-Shenton D; Yh Soong D; Nixon C; O Carragher N; M Carlin L; Kitamura T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472858
[TBL] [Abstract][Full Text] [Related]
18. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma.
Malaisé M; Rovira J; Renner P; Eggenhofer E; Sabet-Baktach M; Lantow M; Lang SA; Koehl GE; Farkas SA; Loss M; Agha A; Campistol JM; Schlitt HJ; Geissler EK; Kroemer A
J Immunol; 2014 Feb; 192(4):1954-61. PubMed ID: 24415778
[TBL] [Abstract][Full Text] [Related]
19. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
